Lavaill Laure, Dussaucy Alain, Bardonnet Karine, Duraffourg Nicolas, Monnet Elisabeth, Thévenot Thierry, Davani Siamak, Di Martino Vincent
aHepatology Department bDepartment of Medical Information cDepartment of Biochemistry dDepartment of informatics eDepartment of Clinical Pharmacology, Besançon University Hospital and University of Franche Comté, France.
Eur J Gastroenterol Hepatol. 2016 Jan;28(1):74-81. doi: 10.1097/MEG.0000000000000464.
BACKGROUND/AIM: We evaluated the relevance of a systematic automatic detection of cirrhosis using biochemical markers in hospitalized patients.
We automatically calculated three free biochemical tests (APRI, Fib-4, and Forns) in patients consecutively hospitalized in our university hospital between July and September, 2010. Patients >18 years not known to suffer from chronic liver disease, were contacted to undergo liver stiffness measurement (LSM) as a reference diagnostic tool. To limit false positives, we required at least one APRI≥2 (indicating cirrhosis) and Fib-4>3.25 and/or Forns>6.9, without obvious overestimation.
A total of 10,035 APRI, 9903 Fib-4, and 1250 Forns were available in 4074 patients. The fibrosis tests were independently influenced by the location of the patient, especially Cardiology (Lower Forns) and Hematology/Oncology Departments (higher APRI, Fib-4, and Forns). Overall, 101 patients (2.48%) were suspected to have cirrhosis. LSM identified two cases of cirrhosis (LSM>13 kPa). In intent-to-diagnose analyses, the highest positive predictive values of the APRI, Fib-4, and Forns for the diagnosis of cirrhosis were 1.98, 1.98, and 11.76%, respectively. The positive predictive value never exceeded 50% in per-protocol analyses when considering patients with numerous positive results of the fibrosis tests.
In hospitalized patients, automatic detection of cirrhosis on the basis of APRI, Fib-4, and Forns was inefficient because of too many false-positive results.
背景/目的:我们评估了在住院患者中使用生化标志物系统自动检测肝硬化的相关性。
我们对2010年7月至9月期间在我校医院连续住院的患者自动计算了三项游离生化检测指标(APRI、Fib-4和Forns)。联系年龄大于18岁且不知患有慢性肝病的患者进行肝脏硬度测量(LSM),作为参考诊断工具。为了限制假阳性,我们要求至少一项APRI≥2(表明肝硬化)且Fib-4>3.25和/或Forns>6.9,且无明显高估。
4074例患者中共有10035项APRI、9903项Fib-4和1250项Forns数据。纤维化检测结果受患者所在科室的独立影响,尤其是心脏病科(较低的Forns)和血液科/肿瘤科(较高的APRI、Fib-4和Forns)。总体而言,101例患者(2.48%)被怀疑患有肝硬化。LSM确诊了2例肝硬化病例(LSM>13 kPa)。在意向性诊断分析中,APRI、Fib-4和Forns诊断肝硬化的最高阳性预测值分别为1.98%、1.98%和11.76%。在符合方案分析中,当考虑纤维化检测结果为多项阳性的患者时,阳性预测值从未超过50%。
在住院患者中,基于APRI、Fib-4和Forns自动检测肝硬化效率低下,因为假阳性结果过多。